Fictional sample | Dermatology

A dermatology Transition Workup, shown as a real decision document.

This fictional example shows the buyer-ready version of a Workup: path read, planning range, transferability, evidence gaps, separate-asset treatment, and next actions.

Request your Workup
Fictional Dermatology sample · illustrative only · not an appraisal

Transition Workup preview

Main Line Dermatology Group

Dermatology practice. Core operating-practice economics only. No PHI included.

RecommendationPrepare for Sale
Path confidenceMedium-high
Range confidenceEvidence-gated
Timeline9-18 months
Primary focusMedical, Mohs, cosmetic mix

Executive summary

The practice is potentially transferable, but specialty evidence should lead the process.

This practice has documented demand and enough operating clarity to justify preparation for a controlled transition process. The owner should assemble source financials and specialty-specific evidence before initiating introductions. The indicative planning range below applies only to core operating-practice economics.

Range bridge

Indicative operating-practice range

$428,000 - $731,000Core practice only
Submitted inputFictional estimate
Business inputTwo-clinician partnership
Business input$1.32M collections
Business input$390,000 replacement compensation estimate
Specialty focusmedical, Mohs, and cosmetic mix, pathology, devices, product inventory, and surveillance continuity
Separate value considerationCosmetic products, device value, and pathology-related economics are treated separately from the core medical practice range.

Transferability scoring

Specialty-specific issues decide whether value can move.

Strong
Demand and workflow

Stable medical dermatology demand; Surveillance and recall workflows; Staff and procedural operating protocols

82%
Moderate
Owner dependency

Owner-specific cosmetic following

58%
Moderate
Referral and staffing durability

Staff and procedural operating protocols

64%
Needs work
Specialty evidence gap

Medical, Mohs, and cosmetic revenue split

42%
Needs work
Separate-asset treatment

Cosmetic products, device value, and pathology-related economics are treated separately from the core medical practice range.

38%
Strong
Continuity planning

medical, Mohs, and cosmetic mix, pathology, devices, product inventory, and surveillance continuity

76%

Evidence requests

What would tighten the range and buyer/successor fit read.

01

Medical, Mohs, and cosmetic revenue split. Document the relevant operating facts and identify what still requires professional review.

02

Surveillance and pathology workflows. Document the relevant operating facts and identify what still requires professional review.

03

Device and inventory schedules. Document the relevant operating facts and identify what still requires professional review.

04

Referral and staffing continuity. Document the relevant operating facts and identify what still requires professional review.

30 / 90 / 365-day priorities

What the owner should do next.

30 days

Normalize financials, identify separate assets, and confirm continuity and records responsibilities.

90 days

Resolve evidence gaps, test credentialing and transfer assumptions, and select an advisor-supported path.

365 days

Execute the chosen transition with controlled introductions and documented continuity safeguards.

Qualified professional advisors must evaluate source documents, state-specific rules, transaction structure, and clinical continuity responsibilities.